Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GBA mutations, glucosylceramide and Parkinson's disease.

Current opinion in neurobiology - 1 Feb 2022

Milenkovic Ivan, Blumenreich Shani, Futerman Anthony H

Abstract excerpt

Mutations in GBA, which encodes the lysosomal enzyme glucocerebrosidase, are the highest genetic risk factor for Parkinson's disease (PD), although the mechanistic link between GBA mutations and PD is unknown. An attractive hypothesis is that the lipid substrate of glucocerebrosidase, glucosylceramide, accumulates in patients with PD with a GBA mutation (PD-GBA). Despite the availability of new and accurate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain
Share to Cellular transport and secretion
Share to Glucosylceramidase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucosylceramides

Share to Lysosomal Storage Disorders Research

Share to Lysosomes

Share to Mutation

Share to Parkinson Disease

Source

Identifiers

PMID: 34883387
DOI: 10.1016/j.conb.2021.11.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GBA mutations, glucosylceramide and Parkinson's disease.PMID 34883387Read ↗

No evidence for substrate accumulation in Parkinson brains with GBA mutations.Semantic proximity Read ↗

Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.Semantic proximity Read ↗

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read ↗

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.Semantic proximity Read ↗

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted TherapySemantic proximity Read ↗

The Consequences of GBA Deficiency in the Autophagy–Lysosome System in Parkinson’s Disease Associated with GBASemantic proximity Read ↗

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic ImplicationsSemantic proximity Read ↗

The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson’s diseaseSemantic proximity Read ↗

Glucocerebrosidase and Parkinson disease: Recent advances.Semantic proximity Read ↗

The role of glucocerebrosidase in Parkinson disease pathogenesis.Semantic proximity Read ↗

The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.Semantic proximity Read ↗

Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.